Make your money go further for just 25p per day

Bioventix (AIM:BVXP) record results from this unusual high margin offering

05/10/2015 · Bioventix (BVXP) 

The developer of high-affinity monoclonal antibodies for applications in clinical diagnostics, announced fantastic audited results for the year ended 30 June 2015. Pre-tax margins of over 70% and superb cash generation highlight the unusual (yet highly attractive) nature of this small business

We published a detailed commentary on this back in April 2015 which is worth a read.

For the year to 30th June 2015 revenue was up 23% to £4.3m and pre-tax profit up 39% to £3.1m (2013/14: £2.2m). The operating cash inflow was also a majestic £2.915m with free cash flow £2m after a modest £113k of capex. Year-end cash was £4.13m after the payment of equity…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Bioventix

Tough end to the quarter | Avenues for growth

31/03/2025 · Company Insights

The escalating trade war sees markets tumble at the close of the quarter. As is generally…


Another AIM offer | Results underwhelm | Tough to value

28/10/2024 · Company Insights

An important week for AIM begins with yet another small AIM company receiving an offer, not…


More Company Insights

Big share price move | Cyber impact | Wine wonders

Record breaking | Back catalogue success | Bonkers Bargains

Sign-up to our free email updates

SIGN UP